RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( ) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: class="ticket-symbol" data-toggle="modal" href="#financial-modal">QURE ) ("uniQure").

On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically, uniQure disclosed that the company believes the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate to provide the primary evidence in support of a BLA submission, and that the timing of the BLA submission for AMT-130 is now unclear as a result.

On this news, the price of uniQure's stock fell over 50%, from a close of $67.69 on October 31, 2025, to close at $34.29 on November 3, 2025.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit .

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
href="/cdn-cgi/l/email-protection#afc6c1c9c0efc4dbc2cc81ccc0c2" target="_blank" rel="nofollow">[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

21% more press release views with Request a Demo

MENAFN10112025003732001241ID1110323941